The functional assay dynamic BH3 profiling (DBP), which helps to select the best drug for each patient, was patented in 2015 by the Dana-Farber Cancer Institute (Boston, United States) and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results